Share price · CANF
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CANF's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 16 Nov 2026+9.9%
Nothing announced by CANF that day or the session before.
- 2 Sep 2026-28.3%
- 2 Jul 2026-15.6%
- 1 Jul 2026+55.9%
- 26 Jun 2026-6.5%
- 9 Jun 2026-5.5%
Nothing announced by CANF that day or the session before.
- 4 May 2026+13.3%
Nothing announced by CANF that day or the session before.
- 5 Mar 2026-23.6%
- 4 Mar 2026+20.4%
- 7 Jan 2026+18.3%
Nothing announced by CANF that day or the session before.
Share of unusual movement by asset
For each asset, the share of CANF's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Adenosine A3 receptor | MASH / NASHHepatocellular Carcinoma | |
| Phase 3 | Adenosine A3 receptorSmall molecule | Psoriasis |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0.4M | $6.7M | $8.5M | $9.8M | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0.7M | $5.8M | $4.8M+ <$0.1M short-term inv. | $2.0M-$7.6M operating cash flow | report ↗ |
| 2023-FY | $0.7M | $6.0M | $4.3M+ <$0.1M short-term inv. | $1.9M-$8.4M operating cash flow | report ↗ |
| 2022-FY | $0.8M | $7.8M | $3.0M+ <$0.1M short-term inv. | $2.5M-$11M operating cash flow | report ↗ |
| 2021-FY | $0.8M | $9.8M | $4.4M+ $0.2M short-term inv. | $3.2M-$9.9M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 14 reporting institutions held 0.1M shares ($329K).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | SABBY MANAGEMENT, LLC | 42,559 | $132K |
| 2 | CITADEL ADVISORS LLC | 34,150 | $106K |
| 3 | RHUMBLINE ADVISERS | 20,908 | $65K |
| 4 | CITIGROUP INC | 5,482 | $17K |
| 5 | UBS Group AG | 2,152 | $7K |
| 6 | OSAIC HOLDINGS, INC. | 450 | $1K |
| 7 | FIFTH THIRD BANCORP | 150 | $465 |
| 8 | WELLS FARGO & COMPANY/MN | 125 | $388 |
| 9 | HRT FINANCIAL LP | 19,383 | $60 |
| 10 | Virtu Financial LLC | 12,908 | $40 |
| 11 | Activest Wealth Management | 10 | $31 |
| 12 | MORGAN STANLEY | 1 | $3 |
| 13 | TD Waterhouse Canada Inc. | 1 | $3 |
| 14 | Avion Wealth | 5 | $0 |